In January 2026, the American Cancer Society announced a 70% cancer survival rate, a statistic that can be misleading to a cancer patient.

Dr. Prato clarifies the nuances behind this data, emphasizing that while there's progress, it largely reflects early-stage disease and not late-stage cancers. Understanding the true incidence and context of these statistics is vital for public health and effective cancer treatment.

🎯 What You’ll Learn in This Episode
• What the 70% cancer survival statistic represents
• Why early-stage cancers influence overall survival numbers
• How metastatic cancer differs biologically
• Why survival rates vary by cancer type and stage
• The role of early detection in improving outcomes
• How deeper testing may guide treatment decisions
• Why individualized approaches are gaining attention
• Questions to ask when reviewing cancer statistics

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Statistics describe populations — but your treatment should be based on your biology.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493